<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01733472</url>
  </required_header>
  <id_info>
    <org_study_id>Hip-CPH-2013</org_study_id>
    <secondary_id>Hässleholm2013</secondary_id>
    <nct_id>NCT01733472</nct_id>
  </id_info>
  <brief_title>General or Regional Anesthesia for Hip Surgery</brief_title>
  <official_title>General Versus Intrathecal Anaesthesia for Patients Undergoing Elective Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether general anaesthesia or regional anaesthesia
      is best for patients undergoing Total Hip Arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled trial (RCT) with a follow up time of 48 hrs. Patients scheduled for
      primary Total Hip Arthroplasty. A total of 120 patients randomly assigned to one of the two
      alternatives (general anaesthesia (GA) or regional anaesthesia (RA)).

      General anaesthesia compared to intrathecal anaesthesia will give shorter length of hospital
      stay (LOS) for patients undergoing total hip arthroplasty (THA).

      Primary endpoint:

      LOS.

      Secondary endpoints:

      Postoperative pain? Postoperative orthostatic function (dizziness) Time until the patient
      meets the discharge criteria from PACU How many patients will need at least one urinary
      bladder catheterisation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Up to 4 days after surgery</time_frame>
    <description>Time from the end of surgery until the patients meets the discharge criteria will be evaluated. Discharge criteria: able to get in and out of bed, Able to get dressed. Able to sit down in a chair and get up again. Able to walk 50 meters wit/without crutches. Able to flex knee 70 degrees. Able to walk stairs. Pain manageable with oral analgesics. Acceptance to be discharged</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Operative Pain</measure>
    <time_frame>from end of surgey until 48 hrs later</time_frame>
    <description>Pain will be monitored using a Visual Analogue Scale. Pain will be monitored with the patient in four different positions. VAS 100 mm used for assessment of pain (0 = no pain, 100 = worst imaginable pain). At each time and position the median VAS-pain score was reported (generally the distribution of pain scores are not normally distributed and hence median value was used)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time Hrs Until the Patient Meets the Discharge Criteria From PACU</measure>
    <time_frame>12 hrs</time_frame>
    <description>Hours until the patient meets the discharge criteria from PACU will be monitored every 15 min from teh time the patient arrives to PACU until he/she meets the discharge criteria</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>RA-arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA-arm, remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GA-arm, remifentanil</intervention_name>
    <description>Remifentanil and propofol will be delivered intravenously via TCI pumps according to the &quot;Marsh&quot; and &quot;Minto&quot; algorithm</description>
    <arm_group_label>GA-arm, remifentanil</arm_group_label>
    <other_name>GA: TCI consisting of remifentanil an propofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RA-arm</intervention_name>
    <description>Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.</description>
    <arm_group_label>RA-arm</arm_group_label>
    <other_name>Regional anesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: patients with osteoarthritis scheduled for surgery

          -  patients that will require THA

          -  patients over 45 yrs and under 85 yrs.

          -  patients that understand the given information and are willing to participate in this
             study

          -  patients who have signed the informed consent document.

          -  patients belonging to ASA class I-III.

        Exclusion Criteria:

          -  prior surgery to the same hip

          -  patients with a history of stroke, neurological or psychiatric disease that
             potentially could affect the perception of pain

          -  obesity (BMI &gt; 35)

          -  active or suspected infection

          -  patients taking opioids or steroids

          -  patients suffering from rheumatoid arthritis or an immunological depression

          -  patients who are allergic to any of the drugs being used in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Harsten, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Skane</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Orthopedic Surgey, Hässleholm Hospital, PO Box 351,</name>
      <address>
        <city>Hässleholm</city>
        <zip>28125</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Fowler SJ, Symons J, Sabato S, Myles PS. Epidural analgesia compared with peripheral nerve blockade after major knee surgery: a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2008 Feb;100(2):154-64. doi: 10.1093/bja/aem373. Review.</citation>
    <PMID>18211990</PMID>
  </reference>
  <reference>
    <citation>Marsh BJ, Morton NS, White M, Kenny GN. A computer controlled infusion of propofol for induction and maintenance of anaesthesia in children. Can J Anaesth. 1990 May;37(4 Pt 2):S97.</citation>
    <PMID>2361330</PMID>
  </reference>
  <reference>
    <citation>Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology. 1997 Jan;86(1):24-33.</citation>
    <PMID>9009936</PMID>
  </reference>
  <reference>
    <citation>Harsten A, Kehlet H, Ljung P, Toksvig-Larsen S. Total intravenous general anaesthesia vs. spinal anaesthesia for total hip arthroplasty. Acta Anaesthesiol Scand. 2015 Apr;59(4):542-3. doi: 10.1111/aas.12495. Epub 2015 Mar 3.</citation>
    <PMID>25736216</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 20, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2012</study_first_posted>
  <results_first_submitted>April 7, 2016</results_first_submitted>
  <results_first_submitted_qc>December 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2019</results_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Skane</investigator_affiliation>
    <investigator_full_name>Andreas Harsten</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>anaesthetic techniques</keyword>
  <keyword>subarachnoid</keyword>
  <keyword>analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RA-arm</title>
          <description>RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
placebo</description>
        </group>
        <group group_id="P2">
          <title>GA-arm, Remifentanil</title>
          <description>GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
GA-arm, remifentanil: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the &quot;Marsh&quot; and &quot;Minto&quot; algorithm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RA-arm</title>
          <description>RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
placebo</description>
        </group>
        <group group_id="B2">
          <title>GA-arm, Remifentanil</title>
          <description>GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
GA-arm, remifentanil: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the &quot;Marsh&quot; and &quot;Minto&quot; algorithm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="9"/>
                    <measurement group_id="B2" value="66" spread="8"/>
                    <measurement group_id="B3" value="67" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Hospital Stay</title>
        <description>Time from the end of surgery until the patients meets the discharge criteria will be evaluated. Discharge criteria: able to get in and out of bed, Able to get dressed. Able to sit down in a chair and get up again. Able to walk 50 meters wit/without crutches. Able to flex knee 70 degrees. Able to walk stairs. Pain manageable with oral analgesics. Acceptance to be discharged</description>
        <time_frame>Up to 4 days after surgery</time_frame>
        <population>Two patients in the RA group were excluded because of the conversion to general anaesthesia.</population>
        <group_list>
          <group group_id="O1">
            <title>RA-arm</title>
            <description>RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
placebo</description>
          </group>
          <group group_id="O2">
            <title>GA-arm, Remifentanil</title>
            <description>GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
GA-arm, remifentanil: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the &quot;Marsh&quot; and &quot;Minto&quot; algorithm</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Time from the end of surgery until the patients meets the discharge criteria will be evaluated. Discharge criteria: able to get in and out of bed, Able to get dressed. Able to sit down in a chair and get up again. Able to walk 50 meters wit/without crutches. Able to flex knee 70 degrees. Able to walk stairs. Pain manageable with oral analgesics. Acceptance to be discharged</description>
          <population>Two patients in the RA group were excluded because of the conversion to general anaesthesia.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="25" upper_limit="45"/>
                    <measurement group_id="O2" value="26" lower_limit="23" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Pain</title>
        <description>Pain will be monitored using a Visual Analogue Scale. Pain will be monitored with the patient in four different positions. VAS 100 mm used for assessment of pain (0 = no pain, 100 = worst imaginable pain). At each time and position the median VAS-pain score was reported (generally the distribution of pain scores are not normally distributed and hence median value was used)</description>
        <time_frame>from end of surgey until 48 hrs later</time_frame>
        <population>Two patients in the RA group were excluded because of the conversion to general anaesthesia.</population>
        <group_list>
          <group group_id="O1">
            <title>RA-arm</title>
            <description>RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
RA-arm: Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.</description>
          </group>
          <group group_id="O2">
            <title>GA-arm, Remifentanil</title>
            <description>GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
GA-arm, remifentanil: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the &quot;Marsh&quot; and &quot;Minto&quot; algorithm</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Pain</title>
          <description>Pain will be monitored using a Visual Analogue Scale. Pain will be monitored with the patient in four different positions. VAS 100 mm used for assessment of pain (0 = no pain, 100 = worst imaginable pain). At each time and position the median VAS-pain score was reported (generally the distribution of pain scores are not normally distributed and hence median value was used)</description>
          <population>Two patients in the RA group were excluded because of the conversion to general anaesthesia.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="20" upper_limit="50"/>
                    <measurement group_id="O2" value="25" lower_limit="0" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time Hrs Until the Patient Meets the Discharge Criteria From PACU</title>
        <description>Hours until the patient meets the discharge criteria from PACU will be monitored every 15 min from teh time the patient arrives to PACU until he/she meets the discharge criteria</description>
        <time_frame>12 hrs</time_frame>
        <population>Two patients in the RA group were excluded because of the conversion to general anaesthesia.</population>
        <group_list>
          <group group_id="O1">
            <title>RA-arm</title>
            <description>RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
RA-arm: Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.</description>
          </group>
          <group group_id="O2">
            <title>GA-arm, Remifentanil</title>
            <description>GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
GA-arm, remifentanil: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the &quot;Marsh&quot; and &quot;Minto&quot; algorithm</description>
          </group>
        </group_list>
        <measure>
          <title>Time Hrs Until the Patient Meets the Discharge Criteria From PACU</title>
          <description>Hours until the patient meets the discharge criteria from PACU will be monitored every 15 min from teh time the patient arrives to PACU until he/she meets the discharge criteria</description>
          <population>Two patients in the RA group were excluded because of the conversion to general anaesthesia.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RA-arm</title>
          <description>RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
placebo</description>
        </group>
        <group group_id="E2">
          <title>GA-arm, Remifentanil</title>
          <description>GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
GA-arm, remifentanil: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the &quot;Marsh&quot; and &quot;Minto&quot; algorithm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <description>atrial fibrillation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andreas Harsten</name_or_title>
      <organization>Region Skane</organization>
      <phone>46708870567</phone>
      <email>andreas.harsten@skane.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

